Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells.

@article{Wang2008GambogicAA,
  title={Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells.},
  author={T. Wang and Jia Wei and X. Qian and Yitao Ding and Lixia Yu and Baorui Liu},
  journal={Cancer letters},
  year={2008},
  volume={262 2},
  pages={
          214-22
        }
}
OBJECTIVE Chemoresistance is a major obstacle to successful cancer chemotherapy. In this study, we examined the ability of gambogic acid (GA) to reverse docetaxel resistance in BGC-823/Doc gastric cancer cells. METHODS The cytotoxic and apoptotic effect of drugs were evaluated by MTT assay and double staining with both Annexin-V-FITC and PI. Cell cycle analysis was determined by PI-stained flow cytometry. Expression of survivin and bcl-2 were evaluated by real-time quantitative RT-PCR… Expand
Synergistic anti-proliferative effects of gambogic acid with docetaxel in gastrointestinal cancer cell lines
Enhancement of anticancer efficacy of chemotherapeutics by gambogic acid against gastric cancer cells.
Anticancer Effect and Apoptosis Induction of Gambogic Acid in Human Leukemia Cell Line K562 In Vitro
Gambogic Acid Sensitizes Ovarian Cancer Cells to Doxorubicin Through ROS-Mediated Apoptosis
YM155, a small molecule inhibitor of survivin expression, sensitizes cancer cells to hypericin-mediated photodynamic therapy.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 51 REFERENCES
Apoptosis-Based Evaluation of Chemosensitivity in Ovarian Cancer Patients
Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer
Repression of telomerase reverse transcriptase mRNA and hTERT promoter by gambogic acid in human gastric carcinoma cells
A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers.
  • M. Monzó, R. Rosell, +7 authors A. Abad
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
...
1
2
3
4
5
...